Still feting donanemab approval, Lilly faces phase 2 failure of tau-targeting med 0 08.08.2024 17:50 Fiercebiotech.com Still feting donanemab approval, Lilly faces phase 2 failure of tau-targeting med aarmstrong Thu, 08/08/2024 - 10:50
